Hylomorph develops membranes and pouches intended to minimize fibrotic tissue build-up and related complications after implant surgery by providing an interface between implant and surrounding tissue. The company’s first commercial focus is a cardiology indication tied to cardiac rhythm management devices, with plans to achieve regulatory approvals and a market launch. Hylomorph says the funding will expand its product portfolio and support clinical development to test safety and efficacy in a large group of patients. Management is also exploring new indications in neurostimulation and the integration of therapeutic agents to increase patient benefits. The company is a Switzerland-based spin-off from ETH Zurich and an alumnus of Wyss Zurich. No operating metrics (revenue/users) were disclosed in the article. Hylomorph is a clinical-stage medtech company based at Technopark Zurich that developed a natural, soft biosynthesised cellulose biomaterial designed to establish an optimal interface with host tissue and prevent inflammatory and foreign-body reactions. Its product portfolio includes the Hylomate Pouch for cardiac implantable electronic devices and neurostimulators, and the Hylomate sheet (20x10 cm) membrane. The company targets primary markets in cardiac rhythm management and neuromodulation, representing a total market opportunity of USD 2.5bn worldwide. Hylomorph says its clinical development program is progressing well and reports encouraging results. The recent financing will support obtaining FDA and CE mark approvals for its product portfolio, beginning with Hylomate. Financially, Hylomorph has secured CHF 5.2 million in a Series B investment plus CHF 0.9 million in non-dilutive funding, totaling CHF 6.1 million.

Total raised

$9M

Funding rounds

4

Latest round

Series B

Latest activity

Dec 2021